Marker Therapeutics Inc. Stock News

Marker Therapeutics Inc (MRKR) shares closed today at 1.9% above its 52 week low of $0.98, giving the company a market cap of $82M. The stock is currently down 31.1% year-to-date, down 34.7% over the past 12 months, and down 78.5% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 44.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Communication Services industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8.6% The company's stock price performance over the past 12 months lags the peer average by 14.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street brokerages predict that Marker Therapeutics, Inc. (NASDAQ:MRKR) will report ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Marker Therapeutics earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.12). Marker Therapeutics reported earnings per share []

Marker Therapeutics (NASDAQ:MRKR) and F-star Therapeutics (NASDAQ:FSTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends. Analyst Recommendations This is a summary of current recommendations and price targets for Marker Therapeutics []

Wall Street brokerages forecast that Marker Therapeutics, Inc. (NASDAQ:MRKR) will report ($0.12) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Marker Therapeutics earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.13). Marker Therapeutics reported earnings of ($0.18) per share during the same quarter []

Marker Therapeutics Inc. (NASDAQ:MRKR) shares, rose in value on Friday, 11/26/21, with the stock price down by 0.00% to the previous days close as strong demand from buyers drove the stock to $1.23. Actively observing the price movement in the last trading, the stock closed the session at $1.23, falling within a range of $1.20 Is Marker Therapeutics Inc. (NASDAQ) Bullish Or Bearish In 2021? Read More »

Marker Therapeutics Inc. (NASDAQ:MRKR) price on Friday, November 19, rose 3.17% above its previous days close as an upside momentum from buyers pushed the stocks value to $1.30. A look at the stocks price movement, the close in the last trading session was $1.26, moving within a range at $1.28 and $1.40. The beta value Marker Therapeutics Inc. (NASDAQ:MRKR) Stock Could Be Worth Considering Read More »

Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock analysts at Oppenheimer boosted their FY2021 earnings per share estimates for Marker Therapeutics in a research report issued to clients and investors on Wednesday, November 10th. Oppenheimer analyst M. Biegler now anticipates that the company will earn ($0.52) per share for the year, up from their previous estimate of []

Equities research analysts expect Marker Therapeutics, Inc. (NASDAQ:MRKR) to post ($0.12) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Marker Therapeutics earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.13). Marker Therapeutics posted earnings per share of ($0.18) in the same quarter []

Marker Therapeutics Inc (NASDAQ: MRKR) received notice of a Product Development Research award of approximately $13.1 million from Texas's Cancer Prevention and Research Institute (CPRIT). The CPRI

The shares of Marker Therapeutics, Inc. (Nasdaq: MRKR) increased by over 15% pre-market. This is why it happened.

HOUSTON, Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi

HOUSTON, Aug. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapie

HOUSTON, July 28, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi

HOUSTON, July 6, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapie

HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi